This report discusses Anthony Fauci's post-government role and the financial connections between his advisory position at an Italian vaccine institute and research funded by his former agency, the NIH.
1. Fauci's New Role: Shortly after leaving his position as Director of the National Institute of Allergy and Infectious Diseases (NIAID) in December 2022, Fauci became an informal strategic advisor for the Fondazione Biotecnopolo di Siena, an institute focused on vaccines and pandemic preparedness.
2. Government Backing: The Biotecnopolo was established under Italian law with support from several government ministries, indicating strong governmental ties and funding allocated towards pandemic preparedness.
3. NIAID Funding: Within months of Fauci joining the institute, NIAID announced a new funding initiative called ReVAMPP, which focused on developing vaccines and monoclonal antibodies for potential pandemics. The institute led by Fauci's associate Rino Rappuoli received a significant portion of this funding.
4. Research Collaboration: Rappuoli, who has collaborated with Fauci for years, was involved as a principal investigator in the NIAID-funded research, which focused on creating vaccines and treatments for various pathogens.
5. Evidence of Financial Links: Biotecnopolo's procurement records reveal that they recorded purchases tied to the NIH-funded ReVAMPP project, providing clear evidence of ongoing connections between Fauci and the funded research.
The relationship between Fauci's role at the Biotecnopolo and the substantial NIH funding showcases a significant overlap between his post-government work and the funding mechanisms he managed for nearly four decades.
No comments:
Post a Comment